OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VRDN
Viridian Therapeutics, Inc.
There isn't enough reported data to score VRDN yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VRDN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
VRDN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VRDN PE Valuation
VRDN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VRDN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VRDN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus VRDN down 190%.
VRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.86 | +$0.44 |
| Q2 2025 | -$4.65 | -$0.41 |
| Q1 2025 | -$4.44 | +$0.05 |
| Q4 2024 | -$4.16 | +$1.15 |
| Q3 2024 | -$4.30 | +$0.82 |
| Q2 2024 | -$4.24 | +$0.65 |
| Q1 2024 | -$4.49 | +$0.19 |
| Q4 2023 | -$5.31 | -$1.26 |
VRDN is still losing money, but far less than before: $3.86 per share over the past year, against $31.75 at its worst in mid-2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VRDN on profitability, with a higher operating margin.
VRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.8M | -64% |
| Q2 2026 | $284K | +279% |
| Q1 2026 | $141K | +96% |
| Q4 2025 | $132K | +83% |
| Q3 2025 | $70.6M | +81958% |
| Q2 2025 | $75K | +4.2% |
| Q1 2025 | $72K | 0% |
| Q4 2024 | $72K | 0% |
VRDN's revenue has slid since its 2025 peak: $26M last quarter, down 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -402% | -345 points |
| Q2 2026 | -44461% | +97895 points |
| Q1 2026 | -82389% | +47980 points |
| Q4 2025 | -92992% | +28497 points |
| Q3 2025 | -57% | +97013 points |
| Q2 2025 | -142356% | -42096 points |
| Q1 2025 | -130369% | -52735 points |
| Q4 2024 | -121489% | -22214 points |
VRDN's operating margin was −402% last quarter, down 345 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VRDN on cash generation, producing positive trailing cash flow while its opponent burns cash.
VRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.1M | -$8.4M |
| Q2 2026 | -$106.6M | -$31.2M |
| Q1 2026 | -$119.7M | -$26.9M |
| Q4 2025 | -$24M | +$49.5M |
| Q3 2025 | -$84.7M | -$16.7M |
| Q2 2025 | -$75.4M | -$29.3M |
| Q1 2025 | -$92.7M | -$47.5M |
| Q4 2024 | -$73.4M | -$35.4M |
VRDN has burned cash in almost every quarter: −$343M over the past year, against −$326M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +266K shares |
| 1 year | +19% | +18.1M shares |
| 3 years | +163% | +70.3M shares |
| 5 years | +2953% | +110M shares |
VRDN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VRDN Net Leverage
VRDN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.2 | Neutral |
| Stochastic | 91.0 | Overbought |
VRDN's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VRDN PE vs Healthcare Sector
VRDN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
VRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.0 | 33% above |
| 20 week MA | $21.9 | 39% above |
| 50 week MA | $23.3 | 31% above |
| 100 week MA | $20.7 | 48% above |
| 200 week MA | $20.4 | 49% above |
VRDN is in an uptrend: it's above all five of its weekly moving averages, and 49% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VRDN on returns for 2026, with the stronger performance.
VRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.62 | $17.6 | +131% |
| 2021 | $17.6 | $21.5 | +22% |
| 2022 | $21.5 | $29.6 | +38% |
| 2023 | $29.6 | $21.8 | -26% |
| 2024 | $21.8 | $19.5 | -11% |
| 2025 | $19.5 | $31.9 | +64% |
| 2026 YTD | $31.9 | $30.5 | -4.4% |
VRDN has finished higher in four of the last six years, two of them by more than 50%. It's down 4.4% so far in 2026.